Long-term assessment of neuropsychiatric adverse reactions associated with efavirenz.
about
Antiretroviral medication: an emerging category of prescription drug misusePharmacokinetic, Pharmacogenetic, and Other Factors Influencing CNS Penetration of AntiretroviralsAssociation between efavirenz as initial therapy for HIV-1 infection and increased risk for suicidal ideation or attempted or completed suicide: an analysis of trial data.No Evidence of an Association Between Efavirenz Exposure and Suicidality Among HIV Patients Initiating Antiretroviral Therapy in a Retrospective Cohort Study of Real World Data.Etravirine in treatment-experienced, HIV-1-infected children and adolescents: 48-week safety, efficacy and resistance analysis of the phase II PIANO study.Neurological and psychiatric tolerability of rilpivirine (TMC278) vs. efavirenz in treatment-naïve, HIV-1-infected patients at 48 weeks.Efavirenz modulation of sleep spindles and sleep spectral profile.Prescription medication misuse among HIV-infected individuals taking antiretroviral therapyOnce-Daily, Single-Tablet Regimens For the Treatment of HIV-1 InfectionDifferential interactions of antiretroviral agents with LXR, ER and GR nuclear receptors: potential contributing factors to adverse eventsThe Expanding Class of Non-Nucleoside Reverse Transcriptase Inhibitors for the Treatment of HIV-1 InfectionInsomnia symptoms and HIV infection among participants in the Women's Interagency HIV Study.Long-term safety from the raltegravir clinical development program.Efavirenz for HIV-1 infection in adults: an overview.Dendritic spine injury induced by the 8-hydroxy metabolite of efavirenz.Recognizing cognitive and psychiatric changes in the post-highly active antiretroviral therapy era.Neuropsychiatric side effects of efavirenz therapy.Efavirenz: a review.Atriplatrade mark - HIV therapy in one pill.Psychiatric morbidity in HIV-infected children.Qualitative study of the quality of sleep in marginalized individuals living with HIV.Antiretroviral therapy using zidovudine, lamivudine, and efavirenz in South Africa: tolerability and clinical events.The impact of pharmacogenetics on HIV therapy.Implications of efavirenz for neuropsychiatry: a review.Clinical management of treatment-experienced, HIV/AIDS patients in the combination antiretroviral therapy era.A systematic review of the psychiatric side-effects of efavirenz.HIV infection and mental health: suicidal behaviour--systematic review.A systematic review of interventions for anxiety in people with HIV.A review of trials investigating efavirenz-induced neuropsychiatric side effects and the implications.Impact of pharmacogenetics on CNS side effects related to efavirenz.Changes in Substance Use Symptoms Across Adolescence in Youth Perinatally Infected with HIV.Depression and anxiety were low amongst virally suppressed, long-term treated HIV-infected individuals enrolled in a public sector antiretroviral program in Thailand.No evident association between efavirenz use and suicidality was identified from a disproportionality analysis using the FAERS database.The emergence of obsessive compulsive and compulsive buying symptomatology after acute stress and short-term use of ribavirin: case reportsQuality of life and depression among HIV-infected patients receiving efavirenz- or protease inhibitor-based therapy in Senegal.Dose reduction of efavirenz: an observational study describing cost-effectiveness, pharmacokinetics and pharmacogenetics.Risk of clinically significant depression in HIV-infected patients: effect of antiretroviral drugs.Molecular mechanisms of serotonergic action of the HIV-1 antiretroviral efavirenz.Changes in sleep quality and brain wave patterns following initiation of an efavirenz-containing triple antiretroviral regimen.8-Hydroxy-efavirenz, the primary metabolite of the antiretroviral drug Efavirenz, stimulates the glycolytic flux in cultured rat astrocytes.
P2860
Q26852974-44020103-75EC-44D1-B392-DF5DD2A0FCFFQ28069383-E1177BB4-BB97-44D6-96EA-B1C904783DC9Q30834094-91941050-505D-47F7-B910-2C4AEA7EBA4DQ31040458-DAFD35F2-7A6C-44B4-A355-AEE2C189B924Q33413634-63024E50-266C-4608-ACA9-F5B900E4DD39Q34035045-148E76D2-83F8-4818-B14B-9364A96A36BFQ34433247-53745ECD-658E-4839-A51B-230A3B39482CQ34602717-C10F365D-8C1F-42FA-B465-A97B6959D1A3Q34976284-620A469E-F1F7-493A-8338-11B06CE69BBBQ35076628-3F8706DA-ACC3-49B7-B8F2-147133D79021Q35111300-E61F34C8-F887-45FB-AA64-4F80FACC3A9DQ35623512-61858040-0DB2-435B-A385-299F90F3295FQ35701258-0A31D425-DE80-4770-8E1B-FB8C668ED3CCQ35917519-18F97B62-D523-433D-9959-65CA7FEF3C58Q36406259-615BED51-ABD4-4145-BC06-3299B44C9206Q36684274-755D7E3F-0713-45D1-8435-33BD083CA256Q36762436-6F34658C-F97B-4C9F-A661-EBA4B1C11601Q36787311-8A3857E0-2D5B-4302-962C-D8FCDF877E5DQ36818184-D80A788B-A033-446B-80EF-C50B88CDFF80Q36851079-CAD5EBDE-C07B-4A13-8C8B-5E5D17706F0CQ36943576-CCCF86E5-1E80-45CA-BE03-D6F1C69F3C6EQ37047864-D6E21F53-FB20-4D3E-B214-B63BD1D4E034Q37405140-8AC14D28-EFBF-4215-9683-1B3137B846ABQ37801927-F2F98785-4976-4191-A0D2-57B54ACFB6BDQ37823558-28ADEF3E-EFCC-4042-B360-96800B504B61Q37864141-3DAD38E2-18DE-4830-A479-B030303F85B4Q37899892-09DB3F8D-1C47-48AD-A932-13EFCC8ABFD7Q37903329-1D14A03E-D897-4CFC-AFAB-99CCB210491FQ38743628-E7522EAF-3985-45AA-91CD-5FEEC799F5C1Q39383647-6A1D0D4F-972D-4488-BDD2-FEC72AA6C4B8Q39637430-60BBD7B2-1285-4CDD-89DE-51982788DEF2Q40523281-75624613-0429-45D4-A607-C3C34E1F2F72Q41752200-4A9B6DAA-91ED-4126-87EB-53F7D578C4D6Q41894499-B8410ADA-0B9C-4CFB-AD00-51AF047443B7Q42164244-4054B07F-BD8E-476C-8446-99734B41EF7EQ42210634-A3C23D9C-B08E-408A-8302-6166B4A26FBCQ42241221-97BA69DE-FDA2-4C66-852A-6069EB1A3BBFQ42592784-9B5C951C-8B67-4D40-8D4F-CE1C6732D7EFQ42683724-901E90FC-4C1C-42D1-8CA9-47FCA4CF8BC4Q43419116-F35811E5-6D84-416D-B669-9A1EABC26BF4
P2860
Long-term assessment of neuropsychiatric adverse reactions associated with efavirenz.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年学术文章
@wuu
2003年学术文章
@zh
2003年学术文章
@zh-cn
2003年学术文章
@zh-hans
2003年学术文章
@zh-my
2003年学术文章
@zh-sg
2003年學術文章
@yue
2003年學術文章
@zh-hant
name
Long-term assessment of neuropsychiatric adverse reactions associated with efavirenz.
@en
Long-term assessment of neuropsychiatric adverse reactions associated with efavirenz.
@nl
type
label
Long-term assessment of neuropsychiatric adverse reactions associated with efavirenz.
@en
Long-term assessment of neuropsychiatric adverse reactions associated with efavirenz.
@nl
prefLabel
Long-term assessment of neuropsychiatric adverse reactions associated with efavirenz.
@en
Long-term assessment of neuropsychiatric adverse reactions associated with efavirenz.
@nl
P2093
P2860
P1433
P1476
Long-term assessment of neuropsychiatric adverse reactions associated with efavirenz.
@en
P2093
P2860
P356
10.1046/J.1468-1293.2003.00136.X
P577
2003-01-01T00:00:00Z